EIN Presswire: Merck Live Feed Press Releases

Codexis Reports Fourth Quarter and Full Year 2011 Results

Tue, 07 Feb 2012 21:05:00 +0000

Codexis Reports Fourth Quarter and Full Year 2011 Results

49% Annual Increase in Pharmaceutical Product Sales

CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol Product Lines Launched

PR Newswire

REDWOOD CITY, Calif., Feb. 7, 2012 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced financial results for the fourth quarter and year ended December 31, 2011.

“In 2011, we launched our CodeXyme™ cellulase enzymes and CodeXol™ detergent alcohol product lines,” said Alan Shaw, Ph.D., President and CEO of Codexis, Inc. “In 2012 we are focused on delivering world-class CodeXyme™ cellulase enzymes to our development partners, piloting production of CodeXol™, and delivering continued sales growth in our pharmaceuticals products and services”.

Full Year 2011 Financial Highlights:

Revenue: For fiscal 2011, the company reported revenues of $123.9 million, an increase of $16.8 million or 16% over fiscal 2010 revenue of $107.1 million. Product revenue of $49.0 million increased $16.2 million or 49% over the prior year, driven by increased sales to both generic and innovator pharmaceutical customers. Collaborative R&D revenue of $71.4 million increased $1.2 million from $70.2 million over the prior year.

Operating Expenses: Research and development expenses for fiscal 2011 were $61.0 million, compared to $52.4 million for fiscal 2010. The increase was primarily due to additional headcount and amortization related to intellectual property purchased from Maxygen, Inc. Selling, general and administrative expenses for fiscal 2011 increased to $36.9 million compared to $33.8 million for fiscal 2010, driven by higher stock compensation expense and higher compensation expense due to headcount increases.

Net Loss: Net loss was ($16.6) million, or ($0.46) per share, based on 35.7 million weighted average common shares outstanding for fiscal year 2011. This compares to a net loss of ($8.5) million or ($0.35) per share for fiscal 2010.

Adjusted EBITDA: On a non-GAAP basis, Adjusted EBITDA was $4.3 million for fiscal 2011 compared to $9.9 million for fiscal 2010. Adjusted EBITDA is calculated by adjusting net loss for net interest expense, income taxes, depreciation, amortization, stock-based compensation and preferred stock warrant fair market valuation. A reconciliation of net loss to Adjusted EBITDA is presented below.

Cash: Cash, cash equivalents and marketable securities at December 31, 2011, was $63.8 million compared to $74.1 million at December 31, 2010. The company used ($0.5) million in cash from operations in fiscal 2011.

Fourth Quarter 2011 Financial Highlights:

Revenue: For the fourth quarter of 2011, the company reported revenues of $33.5 million, an increase of $3.7 million or 12% over $29.8 million in the fourth quarter of 2010. Product revenue increased $6.9 million or 80% over the same time period of 2010.

Operating Expenses: Research and development expenses in the fourth quarter of 2011 were $15.5 million, compared to $13.3 million for the fourth quarter of 2010. The increase was primarily due to additional headcount for the development of CodeXol™ Detergent Alcohol. Selling, general and administrative expenses in the fourth quarter of 2011 increased to $9.8 million, compared to $8.6 million over the same time period of 2010, related to use of consultants, legal costs associated with intellectual property patent filing and increased costs related to SOX compliance.

Net Loss: Net loss was ($5.3) million, or ($0.15) per share, based on 36.0 million weighted average common shares outstanding in the fourth quarter of 2011. This compares to a net loss of ($0.5) million or ($0.01) per share during the fourth quarter of 2010.

Adjusted EBITDA: On a non-GAAP basis, Adjusted EBITDA decreased from $4.4 million in the fourth quarter of 2010 to ($0.2) million in the fourth quarter of 2011. Adjusted EBITDA is calculated by adjusting net loss for net interest expense, income taxes, depreciation, amortization, stock-based compensation and preferred stock warrant fair market valuation. A reconciliation of net loss to Adjusted EBITDA is presented below.

Cash: Cash, cash equivalents and marketable securities at December 31, 2011 was $63.8 million compared to $70.6 million at September 30, 2011. The company used ($2.9) million in cash from operations in the fourth quarter.

Outlook

Codexis' statements with regard to its outlook are based on current expectations. The following statements are forward looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below.

For the full year 2012, Codexis forecasts revenues in line with or exceeding 2011 results. Codexis expects 2012 Adjusted EBITDA will be positive.

Conference Call

Codexis will hold a conference call for investors on February 7, 2012 at 1:30 p.m. PT (4:30 p.m. ET). The conference call dial-in numbers are US: 866-788-0541 or International: 857-350-1679, access code 54501345. A live webcast of the call will also be available from the Investor Relations section of www.codexis.com. A recording of the call will be available by calling US: 888-286-8010 or International: 617-801-6888, access code 84268524 beginning approximately two hours after the call, and will be available for up to thirty days. A webcast replay from today's call will also be available from the Investor Relations section of www.codexis.com approximately two hours after the call and will be available for up to thirty days.

About Codexis, Inc.

Codexis is an industrial biotechnology company developing enzymes for the production of high value sustainable chemicals, clean fuels, cost effective pharmaceutical processes and renewable bioindustrial ingredients to make industry more efficient, productive and profitable. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis' forecast for 2012 revenue and Adjusted EBITDA, and Codexis’ ability to deliver CodeXyme™ cellulase enzymes to its development partners in 2012, pilot production of CodeXol™ in 2012, and deliver sales growth in its pharmaceuticals products and services in 2012. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results include the risks that our operating results may fluctuate in the future, that we have a history of net losses and that we may be unable to successfully commercialize our technology in biofuels. Additional factors that could materially affect actual results can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2011, including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Codexis, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In Thousands, Except Per Share Amounts)

		Three Months Ended			Year Ended
		December 31,			December 31,
		2011	2010	% change	2011	2010	% change
	Revenues:
	Product	$ 15,493	$ 8,586	80%	$ 49,021	$ 32,835	49%
	Collaborative research and development	17,296	20,746	-17%	71,368	70,196	2%
	Government grants	705	479	47%	3,476	4,073	-15%

	Total revenues	33,494	29,811	12%	123,865	107,104	16%

	Costs and operating expenses:
	Cost of product revenues	13,067	8,126	61%	41,781	27,982	49%
	Gross margin $	2,426	460	427%	7,240	4,853	49%
	Gross margin %	16%	5%		15%	15%

	Research and development	15,548	13,349	16%	61,049	52,405	16%
	Selling, general and administrative	9,782	8,649	13%	36,942	33,841	9%
					.	.
	Total costs and operating expenses	38,397	30,124	27%	139,772	114,228	22%

	Loss from operations	(4,903)	(313)	1466%	(15,907)	(7,124)	123%

	Interest income	77	31	148%	273	166	64%
	Interest expense and other, net	(297)	(153)	94%	(675)	(1,199)	-44%

	Loss before provision for income taxes	(5,123)	(435)	1078%	(16,309)	(8,157)	100%

	Provision for income taxes	174	60	190%	241	384	-37%
	Net loss	$ (5,297)	$ (495)	970%	$ (16,550)	$ (8,541)	94%

	Net loss per share of common stock,
	basic and diluted	$ (0.15)	$ (0.01)		$ (0.46)	$ (0.35)

	Weighted average common shares used in computing net loss per share of common stock, basic and diluted	35,965	34,452		35,674	24,594

Codexis, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In Thousands)

	December 31,	December 31,
	2011	2010
Assets
Current assets:
Cash and cash equivalents	$ 25,762	$ 72,396
Marketable securities	27,720	-
Accounts receivable, net	18,917	15,333
Inventories	4,488	2,817
Prepaid expenses and other current assets	2,345	1,646
Total current assets	79,232	92,192

Restricted cash	1,511	1,466
Non-current marketable securities	10,348	1,650
Property and equipment, net	24,176	21,452
Intangible assets, net	16,442	20,158
Goodwill	3,241	3,241
Other non-current assets	972	1,141
Total assets	$ 135,922	$ 141,300

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$ 10,364	$ 9,208
Accrued compensation	6,785	8,107
Other accrued liabilities	7,354	5,630
Deferred revenues	3,789	4,539
Total current liabilities	28,292	27,484

Deferred revenues, net of current portion	1,485	5,074
Other long-term liabilities	3,455	1,381
Total liabilities	33,232	33,939

Stockholders' equity:
Common stock	4	4
Additional paid-in capital	287,792	275,540
Accumulated other comprehensive income (loss)	(407)	(34)
Accumulated deficit	(184,699)	(168,149)
Total stockholders' equity	102,690	107,361
Total liabilities, and stockholders' equity	$ 135,922	$ 141,300

Codexis, Inc.
Condensed Consolidated Statements of Cash Flow
(Unaudited)
(In Thousands)

	Year Ended
	December 31,
	2011		2010
Operating activities:
Net loss	$ (16,550)		$ (8,541)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible assets	3,716		1,063
Depreciation and amortization of property and equipment	7,755		7,246
Revaluation of redeemable convertible preferred stock warrant liability	-	0	677
Loss (gain) on disposal of property and equipment	49		148
Gain from extinguishment of asset retirement obligation	(124)		-
Extinguishment of royalty payable	-		461
Stock-based compensation	9,431		8,737
Accretion of asset retirement obligation	39		146
Amortization of debt discount	-		26
Accretion (amortization) of premium/discount on marketable securities	771		511
Changes in operating assets and liabilities:
Accounts receivable	(3,583)		(8,087)
Inventories	(1,671)		98
Prepaid expenses and other current assets	(682)		13
Other assets	513		2,814
Accounts payable	1,156		(2,105)
Accrued compensation	(1,322)		1,589
Other accrued liabilities	4,351		(6,048)
Deferred revenues	(4,339)		(15,131)
Net cash used in operating activities	(490)		(16,383)

Investing activities:
Increase in restricted cash	(45)		(735)
Purchase of property and equipment	(10,736)		(6,990)
Purchase of marketable securities	(52,564)		(49,051)
Purchase of Maxygen patent portfolio			(20,705)
Proceeds from sale of marketable securities	6,037		1,605
Proceeds from maturities of marketable securities	8,500		70,695
Proceeds from disposal of property and equipment			15
Net cash used in investing activities	(48,808)		(5,166)

Financing activities:
Principal payments on financing obligations	-		(8,026)
Payments in preparation for initial public offering	-		(3,870)
Proceeds from issuance of common stock on IPO, net of underwriting discounts	-	-	72,541
Proceeds from exercises of stock options	2,579		1,594
Net cash provided by financing activities	2,579		62,239

Effect of exchange rate changes on cash and cash equivalents	85		(79)

Net increase (decrease) in cash and cash equivalents	(46,634)		40,611
Cash and cash equivalents:
Beginning of the period	72,396		31,785
End of the period	25,762		72,396

Marketable securities at the end of period	38,068		1,650

Cash, cash equivalents and marketable securities	$ 63,830		$ 74,046


Reclassification of preferred stock warrant from liability to additional paid-in capital			$ 2,686
Conversion of preferred stock to common stock and additional paid-in capital			$ 179,672

Reconciliation of GAAP to Non-GAAP Financial Information

In this press release, in addition to GAAP financial results, we present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA to evaluate the effectiveness of our business strategies.

A reconciliation of GAAP net loss to Adjusted EBITDA is included in the table below.

Codexis, Inc.
Reconciliation of GAAP Net Loss to Adjusted EBITDA
(Unaudited)
(In Thousands)

	Three Months Ended		Year Ended
	December 31,		December 31,
Calculation of Adjusted EBITDA	2011	2010	2011	2010
Net loss	$(5,297)	$ (495)	$(16,550)	$(8,541)
Adjustments:
Minus: Interest income	(77)	(31)	(273)	(166)
Plus: Interest expense	-	5	-	529
Plus: Income taxes	174	60	241	384
Plus: Depreciation and amortization	3,006	2,609	11,471	8,309
Plus: Stock-based compensation	2,038	2,271	9,431	8,737
Plus: Preferred stock warrant fair market valuation adjustment	-	-	-	677

Adjusted EBITDA	$ (156)	$4,419	$ 4,320	$ 9,929

Adjusted EBITDA has limitations as an analytical tool. Some of these limitations are:

Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and
Non-cash compensation is and will remain a key element of our overall long-term incentive compensation package, although we exclude it as an expense when evaluating our ongoing operating performance for a particular period.

Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only supplementally.

Contacts:
Investors: Jay Sarwar, ir@codexis.com, 650-421-8331
Media: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.

SOURCE Codexis, Inc.

HASH(0xaa4e8a0)

Tue, 07 Feb 2012 14:12:51 +0000

WHITEHOUSE STATION, N.J., Feb. 7, 2012 - Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced the top-line results of the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events) study of vorapaxar. Merck is developing vorapaxar, an investigational oral Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist, for the prevention of thrombosis, or clot formation, and the reduction of cardiovascular events.

TRA-2P showed that the addition of vorapaxar to standard of care significantly reduced the risk of the protocol-specified primary endpoint of the composite of cardiovascular death (CVD), heart attack (myocardial infarction, or MI), stroke or urgent coronary revascularization compared to standard of care. There was a significant increase in bleeding, including intracranial hemorrhage (ICH), among patients taking vorapaxar in addition to standard of care, although there was a lower risk of ICH in patients without a history of stroke.

The full results of TRA-2P will be presented at the American College of Cardiology Scientific Sessions in March.

"In developing vorapaxar, Merck and our scientific collaborators set a very high bar – would the addition of vorapaxar to standard of care provide incremental benefit in preventing clots?" said Peter S. Kim, president, Merck Research Laboratories. "We are pleased that TRA-2P met its primary endpoint, and we look forward to discussing the results with the scientific community."

Merck will review the data from both TRA2-P and TRACER with the investigators and other outside experts to help better understand the profile of this investigational medicine in specific patient populations and to determine next steps, including potential regulatory filings.

Vorapaxar has been evaluated in two major clinical outcomes studies: TRA-2P TIMI 50 (Clinicaltrials.gov identifier: NCT00526474 ) was led by the Thrombolysis in Myocardial Infarction (TIMI) Study Group of Brigham and Women's Hospital. TRA-2P was a secondary prevention study in 26,449 patients with a heart attack, an ischemic stroke, or documented peripheral vascular disease. TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), (Clinicaltrials.gov identifier: NCT00527943) was an acute care, hospital-based study of approximately 12,944 patients with non-ST-segment-elevation acute coronary syndrome. The study was led by the Duke Clinical Research Institute, and results were presented in 2011 at the American Heart Association Scientific Sessions and published in the January 5, 2012 issue of The New England Journal of Medicine (Vol. 366, No. 1). The news release can be found at http://www.merck.com/newsroom/news-release-archive/research-and-development/2011_1113.html.

About Merck
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement
This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the United States and internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2010 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia

Tue, 07 Feb 2012 09:12:39 +0000

WHITEHOUSE STATION, N.J., Feb. 6, 2012 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if approved, will be a new mechanism for the treatment of insomnia. The two pivotal Phase III efficacy trials for suvorexant have been completed and, based on the positive results of these studies, Merck plans to file a New Drug Application (NDA) for suvorexant with the U.S. Food and Drug Administration (FDA) in 2012.

Both Phase III studies were multicenter, randomized, double-blind, placebo-controlled clinical trials that evaluated suvorexant compared to placebo in adult patients ages 18 years and older. The primary endpoint was change from baseline in subjective total sleep time and time to sleep onset, wake time after persistent sleep onset, and latency to onset of persistent sleep at one and three months. Merck plans to submit these data for presentation at major medical meetings later this year.

Suvorexant is one of the five major U.S. filings Merck anticipates for 2012 and 2013.

"Suvorexant selectively targets an important pathway involved in helping to promote sleep and, if approved, will be a new, first-in-class treatment for patients with insomnia," said Peter S. Kim, president, Merck Research Laboratories. "We are enthusiastic about the potential of this investigational medicine, and look forward to sharing the results from these studies with the medical community."

Auxilium Announces Appointments to Enhance Leadership Team

Mon, 06 Feb 2012 14:15:00 +0000

Auxilium Announces Appointments to Enhance Leadership Team

Andrew I. Koven Named Executive Vice President, Chief Administrative Officer and General Counsel

Mark A. Glickman Named Senior Vice President, Sales

PR Newswire

MALVERN, Pa., Feb. 6, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced the appointment of two executive officers, effective immediately. Andrew I. Koven has been named Executive Vice President, Chief Administrative Officer and General Counsel, and Mark A. Glickman has been named Senior Vice President, Sales.

"The leadership appointments we are announcing today advance our efforts to help position Auxilium for sustainable success and the next stage of its evolution," said Adrian Adams, Chief Executive Officer and President of Auxilium. "Collectively, Andrew and Mark's broad expertise and industry experience should significantly enhance our capabilities as we seek to maximize the value of XIAFLEX® and Testim®, deliver on our current pipeline, and capitalize on future growth opportunities to achieve profitability and drive shareholder value."

Mr. Koven has over 26 years of experience practicing law, most of which has been in the pharmaceutical industry. He most recently served as President and Chief Administrative Officer of Neurologix, Inc. Prior to that, Mr. Koven was Executive Vice President and Chief Administrative and Legal Officer at Inspire Pharmaceuticals, Inc., where he oversaw all matters related to legal, quality and compliance, corporate development and licensing and technical operations prior to the strategic acquisition of the company by Merck & Co. From 2007 to 2010 Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Sepracor Inc. before its acquisition by Dainippon Sumitomo Pharma Co in 2009. Before joining Sepracor, Mr. Koven was Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc., where he oversaw the company's legal, compliance and quality assurance departments until the acquisition of the company by Abbott Laboratories in 2006. Mr. Koven began his career in the pharmaceutical industry as an Assistant General Counsel at Warner-Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. From 1986 to 1992 he was a corporate associate at Cahill, Gordon & Reindel in New York. In his new role, Mr. Koven will be assuming responsibility for the Company's legal functions, government affairs and technical operations.

Mr. Glickman has over 20 years of experience in pharmaceutical sales and operations, with expertise in a variety of fields including sales turnarounds, global product introductions and organizational expansions. Most recently he was Vice President of the medical device division of Otsuka America Pharmaceutical, Inc., a U.S. division of the Tokyo-based Otsuka Pharmaceutical Company. At Otsuka, he helped to reinvigorate the company's sales and increase its business by 50% over two years, while also spearheading quality improvement initiatives and playing a critical role in new regulatory filings. Prior to that, he served as Senior Vice President of Sales and Marketing at Oscient Pharmaceuticals Corp., from 2007 to 2009, during which time he completed a successful turnaround of the company's commercial strategy, driving a significant increase in sales during his tenure. Before joining Oscient, Mr. Glickman served as Vice President of Sales at Bayer Healthcare's Diabetes Care Division. From 2001 to 2007 he played a major role in helping to build the commercial organization at Kos Pharmaceuticals by holding various positions including Director of Marketing, Regional Sales Director and Vice President of Sales. Prior to that, he was a Senior Product Manager at Bristol-Myers Squibb, where, during his tenure, he contributed to revenue growth of $400 million.

The Company also announced the departures of Jennifer Evans Stacey, Esq., the Company's Executive Vice President, General Counsel, and Secretary; Ed Kessig, Senior Vice President, Sales; and Edward Arcuri, Executive Vice President, Technical Operations.

"On behalf of the Auxilium Board of Directors and senior management team, I would like to thank Jennifer, Ed, and Edward for their contributions to the Company over the years," continued Mr. Adams. "Each has played an important role in Auxilium's successes and we wish them well in their future endeavors."

Auxilium also announced today the appointment of Darrin Bryan as Vice President, Commercial Analytics, a newly created position. The addition of this role is consistent with the Company's focus on excellence in execution and driving the successful commercialization of Auxilium's current and future pipeline. The Company expects to benefit from Mr. Bryan's extensive background in sales and marketing strategic analysis.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism in the U.S. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has three projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease, in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and in phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's prospects for profitability, success and growth; the Company's ability to maximize the value of its current products and product pipeline; the strength of the Company's market opportunity; the Company's future financial and operational performance; the Company's ability to commercialize its product pipeline; the Company's future market position; the creation of value for shareholders; and products in development for Peyronie's disease, Frozen Shoulder syndrome and cellulite.

Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.

A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended September 30, 2011, which are on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.

CONTACT:

James E. Fickenscher
Chief Financial Officer
Auxilium Pharmaceuticals, Inc.
+1-484-321-5900
jfickenscher@auxilium.com

William Q. Sargent Jr.
Vice-President, Investor Relations and Corporate Communications
Auxilium Pharmaceuticals, Inc.
+1-484-321-5900
wsargent@auxilium.com

SOURCE Auxilium Pharmaceuticals, Inc.

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Mon, 06 Feb 2012 09:20:01 +0000

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

PR Newswire

NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

http://www.reportlinker.com/p0769058/Commercializing-Angiogenesis-Affecting-Drugs-in-Cancer-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This report will excel your competitive awareness and decrease your decision making time in managing angiogenesis affecting drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

A large number of drugs, both on the market and in development have angiogenesis affecting properties.This report includes both direct angiogenic targets (angiogenesis-related targets) and indirect angiogenic targets (non-angiogenic targets which nevertheless have angiogenesis effects).

This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the angiogenesis affecting drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of angiogenesis affecting drugs in cancer is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 44 different clusters. The latter has a competing ratio which is almost two times higher than the comparable average of the angiogenesis affecting drugs in general.

* Eight out of every ten drug target strategies in Phase III development are new to angiogenesis affecting drugs, whereas only five out of every ten target strategies in Phase II are new.

* The greatest number of new target strategies are found in Preclinical (21%) and Phase II (18%) development.

* Small molecules, Antibodies and Proteins drugs are the dominating compound strategies of angiogenesis affecting cancer drugs, which represent almost 80% of the entire pipeline.

* Protein based angiogenesis affecting cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies and Gene therapies.

* Angiogenesis affecting drugs are experiencing targeting competition in five out of every ten cancer indications described, and more so in colorectal cancer, breast cancer and non-small cell lung cancer..

* The highest number of described target strategies among angiogenesis affecting drugs are found in colorectal cancer, breast cancer, non-small cell lung cancer and ovarian cancer.

* The highest number of described drug target strategies of angiogenesis affecting drugs belongs to Pfizer, Novartis, Abbott, Eli Lilly, EntreMed and Exelixis.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any angiogenesis affecting drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.1 Executive Summary 32 About Cancer Highlights™ 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 63 Methodology 73.1 Cancer Highlights'™ Five Pillar Drug Assessment 74 Table of Contents 94.1 List of Figures 224.2 List of Tables225 Introduction 375.1 The Scope of this Report 375.2 Definitions 405.3 Abbreviations 406 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment 416.1 Drug Repositioning in Oncology 416.2 Introduction to Targets of Angiogenesis Affecting Drugs in Oncology 426.2.1 Calcium Ion Binding Targets 486.2.2 Carboxy-lyase Activity Targets 496.2.3 Catalytic Activity Targets 516.2.4 Cell Adhesion Molecule Activity Targets 566.2.5 Chaperone Activity Targets 636.2.6 Chemokine Activity Targets 676.2.7 Cofactor Binding Targets 696.2.8 Cysteine-type Peptidase Activity Targets 716.2.9 Cytokine Activity Targets 766.2.10 Cytoskeletal Protein Binding Targets 806.2.11 DNA Topoisomerase Activity Targets 816.2.12 DNA-directed DNA Polymerase Activity Targets 846.2.13 Extracellular Matrix Structural Constituent Targets 856.2.14 G-protein Coupled Receptor Activity Targets 916.2.15 Growth Factor Activity Targets 966.2.16 GTPase Activity Targets 1126.2.17 Hormone Activity Targets 1156.2.18 Hydrolase Activity Targets 1166.2.19 Kinase Activity Targets 1186.2.20 Kinase Binding Targets 1216.2.21 Lipid Kinase Activity Targets 1236.2.22 Metallopeptidase Activity Targets 1306.2.23 Molecular Function Unknown Targets 1486.2.24 Motor Activity Targets 1496.2.25 Oxidoreductase Activity Targets 1516.2.26 Peptidase Activity Targets 1536.2.27 Phosphoric Diester Hydrolase Activity Targets 1696.2.28 Protease Inhibitor Activity Targets 1726.2.29 Protein Binding Targets 1766.2.30 Protein Serine/Threonine Kinase Activity Targets 1806.2.31 Protein-tyrosine Kinase Activity Targets 2096.2.32 Receptor Activity Targets 2206.2.33 Receptor Binding Targets 2456.2.34 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 2516.2.35 RNA Binding Targets 2536.2.36 Serine-type Peptidase Activity Targets 2546.2.37 Structural Constituent of Cytoskeleton Targets 2596.2.38 Superoxide Dismutase Activity Targets 2616.2.39 Transcription Factor Activity Targets 2646.2.40 Transcription Regulator Activity Targets 2776.2.41 Transferase Activity Targets 2846.2.42 Translation Regulator Activity Targets 2866.2.43 Transmembrane Receptor Activity Targets 2936.2.44 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 2956.2.45 Transporter Activity Targets 3486.2.46 Ubiquitin-specific Protease Activity Targets 3526.2.47 Unknown Function Targets 3536.2.48 Voltage-gated Ion Channel Activity Targets 3546.3 The Cancer Genome Project and Targets of Angiogenesis Affecting Drugs in Oncology 3556.3.1 Targets of Angiogenesis Affecting Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 3556.4 Angiogenesis Affecting Therapeutics is Stimulated by Available Structure Data on Targets 3606.5 Target-Target Interactions among Identified Targets of Angiogenesis Affecting Drugs in Oncology 3646.6 The Drug-Target Competitive Landscape 3686.7 Protein Expression Levels of Identified Targets of Angiogenesis Affecting Drugs in Oncology 3726.8 Pathway Assessment of Angiogenesis Affecting Drugs in Oncology 3756.8.1 Tools for Analysis of Cancer Pathways 3766.8.2 Pathway Assessment 3777 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development 4247.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4267.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4287.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4317.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4387.5 Preclinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4467.6 Drug Target Strategies of No Data, Suspended or Terminated Angiogenesis Affecting Drugs in Oncology 4507.7 Target Strategy Development Profiles of Angiogenesis Affecting Drugs in Oncology 4547.7.1 Marketed 4587.7.2 Pre-registration 4737.7.3 Phase III 4777.7.4 Phase II 5157.7.5 Phase I 5517.7.6 Preclinical 5827.7.7 Suspended 6187.7.8 Ceased 6197.8 The Competition Through Close Mechanistic Approximation of Angiogenesis Affecting Drugs in Oncology 6608 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy 6678.1 Small Molecules 6698.1.1 Background 6698.1.2 Target Strategies of Small Molecule Drugs 6708.2 Peptide & Protein Drugs 6828.2.1 Background 6828.2.2 Target Strategies of Peptide and Protein Drugs 6838.3 Antibodies 6898.3.1 Background 6898.3.2 Target Strategies of Antibody Drugs 6898.4 Nucleic Acid Therapies 6948.4.1 Background 6948.4.2 Target Strategies of Nucleic Acid Drugs 6958.5 Gene Therapy 6978.5.1 Background 6978.5.2 Target Strategies of Gene Therapy Drugs 6978.6 Drug Delivery and Nanotechnology 7008.6.1 Background 7008.6.2 Target Strategies of Reformulated Drugs 7008.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 7039 Selecting Indication for Angiogenesis Affecting Drugs in Oncology 7109.1 Acute Lymphocytic Leukemia 7139.2 Acute Myelogenous Leukemia 7149.3 Adrenal Cancer 7179.4 B-cell Lymphoma 7189.5 Basal Cell Cancer 7199.6 Biliary Cancer 7209.7 Bladder Cancer 7219.8 Bone Cancer 7249.9 Brain Cancer 7259.10 Breast Cancer 7289.11 Cancer (general) 7349.12 Carcinoid 7359.13 Cervical Cancer 7379.14 Chemopreventative 7389.15 Chronic Lymphocytic Leukemia 7399.16 Chronic Myelogenous Leukemia 7409.17 Chronic Myelomonocytic Leukemia 7419.18 CNS Cancer 7419.19 Colorectal Cancer 7429.20 Endometrial Cancer 7489.21 Fallopian Tube Cancer 7509.22 Fibro Sarcoma 7529.23 Gastrointestinal Cancer (general) 7539.24 Gastrointestinal Stomach Cancer 7569.25 Gastrointestinal Stromal Cancer 7599.26 Head and Neck Cancer 7619.27 Hematological Cancer (general) 7649.28 Hodgkin's Lymphoma 7659.29 Kaposi's Sarcoma 7669.30 Leiomyo Sarcoma 7679.31 Leukemia (general) 7689.32 Lipo Sarcoma 7699.33 Liver Cancer 7709.34 Lung Cancer (general) 7749.35 Lymphangioleiomyomatosis 7769.36 Lymphoma (general) 7779.37 Mast Cell Leukemia 7799.38 Mastocytosis 7799.39 Melanoma 7809.40 Mesothelioma 7849.41 Myelodysplastic Syndrome 7879.42 Myeloma 7899.43 Nasopharyngeal Cancer 7929.44 Neuroendocrine Cancer (general) 7939.45 Neuroendocrine Cancer (pancreatic) 7949.46 Neurofibromatosis 7969.47 non-Hodgkin's Lymphoma 7979.48 Non-Small Cell Lung Cancer 7999.49 Oesophageal Cancer 8059.50 Oral Cancer 8079.51 Osteo Sarcoma 8089.52 Ovarian Cancer 8099.53 Pancreatic Cancer 8139.54 Peritoneal Cancer 8169.55 Prostate Cancer 8189.56 Radio/chemotherapy-induced Alopecia 8229.57 Radio/chemotherapy-induced Infection 8229.58 Renal Cancer 8239.59 Sarcoma (general) 8289.60 Small Cell Lung Cancer 8309.61 Soft Tissue Sarcoma 8339.62 Solid Tumor 8359.63 Squamous Cell Cancer 8399.64 Synovial Sarcoma 8409.65 T-cell Lymphoma 8419.66 Testicular Cancer 8429.67 Thyroid Cancer 8439.68 Unspecified 8459.69 Vaccine adjunct 8489.70 Waldenstrom's hypergammaglobulinemia 84810 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator 84910.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 85310.2 Company Facts and Ranking 85510.3 Competitive Fall-Out Assessment 86110.4 Abbott 86410.5 Acceleron Pharma 87510.6 Access 87910.7 Active Biotech 88310.8 Adherex 88710.9 Advantagene 89510.10 Advaxis 90110.11 Advenchen 90510.12 Aeterna Zentaris 90910.13 Agennix 91610.14 Aida Pharmaceuticals 92010.15 Alnylam 92410.16 Ambit Biosciences 92810.17 Ambrilia Biopharma 93410.18 Amgen 93810.19 Amphora 94610.20 Angiogen 95010.21 Angiogenex 95410.22 Angstrom Pharmaceuticals 95810.23 Ansaris 96210.24 Antisoma 96610.25 Arana Therapeutics 97010.26 Ariad 97410.27 Arno Therapeutics 98410.28 ArQule 98810.29 Array BioPharma 99410.30 Astellas 99810.31 Astex Therapeutics 100410.32 AstraZeneca 100810.33 Attenuon 101610.34 Austrianova 102210.35 Bayer 102610.36 BioAlliance Pharma 103610.37 BioAxone 104110.38 Biocad 104510.39 Boehringer Ingelheim 105110.40 Bolder BioTechnology 105710.41 Bristol-Myers Squibb 106310.42 BTG 107510.43 Cancer Research Technology 108110.44 CDG Therapeutics 108510.45 Celecure 108910.46 Celera 109310.47 Celgene 109710.48 Cell Therapeutics 110510.49 CellCeutix 111010.50 Cellmid 111410.51 Cephalon 111810.52 ChemoCentryx 112210.53 Chemokine Therapeutics 112610.54 China Sky One Medical 113010.55 Choongwae 113410.56 Circadian Technologies 113910.57 Cue Biotech 114410.58 Curis 114810.59 Cyclacel 115410.60 Cytochroma 115810.61 Deciphera Pharmaceuticals 116210.62 Dendreon 116610.63 Dyax 117010.64 Eisai 117410.65 Eli Lilly 118110.66 EntreMed 119510.67 Exelixis 120610.68 ExonHit Therapeutics 121810.69 Five Prime Therapeutics 122210.70 GammaCan 122610.71 Genmab 123310.72 Gilead Sciences 124010.73 GlaxoSmithKline 124710.74 GlycoGenesys 125410.75 Green Cross 125910.76 Hoffmann-La Roche 126410.77 Hy BioPharma 127610.78 Idera Pharmaceuticals 128010.79 ImClone Systems 128710.80 ImmunoGen 129210.81 ImmuPharma 129610.82 Introgen Therapeutics 130010.83 Isis Pharmaceuticals 130510.84 Johnson & Johnson 130910.85 KAI Pharmaceuticals 131710.86 Karus Therapeutics 132210.87 Kirin Pharma 132610.88 Kringle Pharma 133010.89 Kyowa Hakko Kirin 133410.90 Lee's Pharmaceutical 134010.91 Lorus Therapeutics 134410.92 MAT Biopharma 134810.93 MediGene 135210.94 Merck & Co 135810.95 Merck KGaA 136210.96 Mersana Therapeutics 136910.97 MethylGene 137310.98 Micromet 137710.99 MolMed 138110.100 Morvus Technology 138610.101 NewSouth Innovations 139010.102 Non-industrial Source 139410.103 Novartis 139810.104 Novelix 141710.105 Noxxon 142110.106 Oasmia 142510.107 Onconova 142910.108 OncoTherapy Science 143510.109 Oncothyreon 144110.110 OSI Pharmaceuticals 144610.111 Oxford BioMedica 145110.112 OXiGENE 145510.113 Pepscan Therapeutics 146110.114 PepTx 146810.115 Peregrine Pharmaceuticals 147210.116 Pfizer 147910.117 Pharmacopeia 149910.118 PharmaMar 150410.119 Pharminox 151010.120 Philogen 151410.121 PhiloGene 151810.122 Pierre Fabre 152210.123 Progen 152810.124 Protein Sciences 153210.125 Protgen 153710.126 PTC Therapeutics 154210.127 Receptor BioLogix 154910.128 Regeneron 155310.129 Rexahn 156110.130 Rigel 156510.131 Sanofi 156910.132 Santaris Pharma 157610.133 Scancell 158210.134 SciClone Pharmaceuticals 158610.135 Semafore Pharmaceuticals 159010.136 Shionogi 159610.137 Simcere Pharmaceuticals 160010.138 Spear Therapeutics 160810.139 SRI International 161210.140 Stainwei Biotech 161810.141 SuperGen 162210.142 Switch Pharma 162610.143 SynDevRx 163010.144 Taiho 163410.145 Tau Therapeutics 163810.146 ThromboGenics 164210.147 Tigris Pharmaceuticals 164610.148 ToolGen 165010.149 TopoTarget 165710.150 Tracon Pharmaceuticals 166110.151 UCB 166510.152 VBL Therapeutics 167210.153 Wilex 167610.154 Xerion 168211 Disclaimer 168612 Drug Index 168713 Company Index 1697

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 367Figure 2: The Drug-Target Competitive Landscape of Angiogenesis Affecting Drugs in Oncology - Large Cluster 369Figure 3: The Drug-Target Competitive Landscape Angiogenesis Affecting Drugs in Oncology - Smaller Clusters 370Figure 4: Head-to-Head Targeting Competitive Landscape of Angiogenesis Affecting Drugs in Oncology 371Figure 5: Distribution of Compound Strategies among Angiogenesis Affecting Cancer Drugs 703Figure 6: Primary Sub-cellular Localization of Drug Targets 704Figure 7: Number of Companies per Ranking Level 855

4.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7Table 2: Breakdown of the Included Angiogenesis Affecting Drug Pipeline in Oncology by Stage of Development 37Table 3: Head to Head Target Competition among Angiogenesis Affecting Drugs in Oncology 37Table 4: Overview of Drug Target Strategy Themes 42Table 5: Terminally Ceased Targets of Angiogenesis Affecting Drugs in Oncology 43Table 6: Official Gene Name to Target Profle 44Table 7: Targets of Angiogenesis Affecting Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 356Table 8: Identity of Drug Targets with Available Biological Structures 360Table 9: Number of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 365Table 10: Available Protein Expression Profiles of Angiogenesis Affecting Drug Targets in Oncology 372Table 11: Pathway Summary 377Table 12: Drug Targets without any Identified Assigned Pathways 377Table 13: Pathway Profiles According to BioCarta of Angiogenesis Affecting Drug Targets in Oncology 379Table 14: Pathway Profiles According to KEGG of Angiogenesis Affecting Drug Targets in Oncology 397Table 15: Pathway Profiles According to NetPath of Angiogenesis Affecting Drug Targets in Oncology 417Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 424Table 17: Top Competitive Target Strategies of Angiogenesis Affecting Drugs in Oncology 425Table 18: New and Unique Target Strategies of Pre-registration and Marketed Angiogenesis Affecting Drugs in Oncology 426Table 19: The Competition Through Close Mechanistic Approximation Between Angiogenesis Affecting Drugs in Oncology in Pre-registration to Marketed 427Table 20: New and Unique Target Strategies in Phase III Clinical Development of Angiogenesis Affecting Drugs in Oncology 428Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Angiogenesis Affecting Drugs in Oncology 430Table 22: New and Unique Target Strategies in Phase II Clinical Development of Angiogenesis Affecting Drugs in Oncology 431Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Angiogenesis Affecting Drugs in Oncology 435Table 24: New and Unique Target Strategies in Phase I Clinical Development of Angiogenesis Affecting Drugs in Oncology 438Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Angiogenesis Affecting Drugs in Oncology 442Table 26: New and Unique Target Strategies in Preclinical Development of Angiogenesis Affecting Drugs in Oncology 446Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Angiogenesis Affecting Drugs in Oncology 449Table 28: Target Strategies of No Data, Suspended and Terminated Angiogenesis Affecting Drugs in Oncology 450Table 29: Connecting Target Strategy with Its Profile Identification Number 454Table 30: The Competition Through Close Mechanistic Approximation Among Angiogenesis Affecting Drugs in Oncology 660Table 31: Overview of Compound Strategy Competition Among Angiogenesis Affecting Cancer Drugs 668Table 32: Overview of the Competitive Landscape of Small Molecule Based Angiogenesis Affecting Cancer Drugs 670Table 33: Competitive Comparison of Target Strategies of Small Molecule Angiogenesis Affecting Cancer Drugs 671Table 34: Pursued Target Strategies of Small Molecule Drugs Based Angiogenesis Affecting Cancer Drugs 675Table 35: Overview of the Competitive Landscape of Peptide Based Angiogenesis Affecting Cancer Drugs 683Table 36: Competitive Comparison of Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs 684Table 37: Pursued Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs 684Table 38: Overview of the Competitive Landscape of Protein Based Angiogenesis Affecting Cancer Drugs 686Table 39: Competitive Comparison of Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs 687Table 40: Pursued Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs 687Table 41: Overview of the Competitive Landscape of Antibody Based Angiogenesis Affecting Cancer Drugs 689Table 42: Competitive Comparison of Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs 690Table 43: Pursued Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs 691Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 695Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 696Table 46: Pursued Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 696Table 47: Vectors in Gene Therapy 697Table 48: Overview of the Competitive Landscape of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 697Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 698Table 50: Pursued Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 699Table 51:Overview of the Competitive Landscape of Reformulated Angiogenesis Affecting Cancer Drugs 700Table 52: Competitive Comparison of Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs 701Table 53: Pursued Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs 702Table 54: Compound Strategies based on Sub-Cellular Localization of Angiogenesis Affecting Cancer Drug Targets 704Table 55 Competitive Summary by Cancer Indication of Angiogenesis Affecting Drugs 711Table 56: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Lymphocytic Leukemia 713Table 57: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Myelogenous Leukemia 714Table 58: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 715Table 59: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Adrenal Cancer 717Table 60: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs 717Table 61: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of B-cell Lymphoma 718Table 62: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Basal Cell Cancer 719Table 63: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Biliary Cancer 720Table 64: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bladder Cancer 721Table 65: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 722Table 66: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bone Cancer 724Table 67: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Brain Cancer 725Table 68: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 727Table 69: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Breast Cancer 728Table 70: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 730Table 71: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer (general) 734Table 72: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Carcinoid 735Table 73: The Competition through Close Mechanistic Approximation between Carcinoid Drugs 736Table 74: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cervical Cancer 737Table 75: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemopreventative 738Table 76: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Lymphocytic Leukemia 739Table 77: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelogenous Leukemia 740Table 78: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelomonocytic Leukemia 741Table 79: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of CNS Cancer 741Table 80: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Colorectal Cancer 742Table 81: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 745Table 82: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Endometrial Cancer 748Table 83: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs 749Table 84: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fallopian Tube Cancer 750Table 85: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 751Table 86: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fibro Sarcoma 752Table 87: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Cancer (general) 753Table 88: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 755Table 89: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stomach Cancer 756Table 90: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 757Table 91: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stromal Cancer 759Table 92: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 760Table 93: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Head and Neck Cancer 761Table 94: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 763Table 95: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hematological Cancer (general) 764Table 96: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hodgkin's Lymphoma 765Table 97: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Kaposi's Sarcoma 766Table 98: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leiomyo Sarcoma 767Table 99: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leukemia (general) 768Table 100: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lipo Sarcoma 769Table 101: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Liver Cancer 770Table 102: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 772Table 103: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lung Cancer (general) 774Table 104: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphangioleiomyomatosis 776Table 105: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphoma (general) 777Table 106: The Competition through Close Mechanistic Approximation between Lymphoma Drugs 778Table 107: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mast Cell Leukemia 779Table 108: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mastocytosis 779Table 109: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Melanoma 780Table 110: The Competition through Close Mechanistic Approximation between Melanoma Drugs 782Table 111: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mesothelioma 784Table 112: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 786Table 113: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myelodysplastic Syndrome 787Table 114: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myeloma 789Table 115: The Competition through Close Mechanistic Approximation between Myeloma Drugs 790Table 116: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Nasopharyngeal Cancer 792Table 117: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (general) 793Table 118: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (pancreatic) 794Table 119: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs 794Table 120: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neurofibromatosis 796Table 121: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of non-Hodgkin's Lymphoma 797Table 122: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 798Table 123: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Non-Small Cell Lung Cancer 799Table 124: The Competition through Close Mechanistic Approximation between non-Small Cell Lung Cancer Drugs 802Table 125: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oesophageal Cancer 805Table 126: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 806Table 127: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oral Cancer 807Table 128: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Osteo Sarcoma 808Table 129: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Ovarian Cancer 809Table 130: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 811Table 131: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Pancreatic Cancer 813Table 132: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 815Table 133: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Peritoneal Cancer 816Table 134: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 817Table 135: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Prostate Cancer 818Table 136: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 820Table 137: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Alopecia 822Table 138: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Infection 822Table 139: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Renal Cancer 823Table 140: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 826Table 141: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Sarcoma (general) 828Table 142: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 829Table 143: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Small Cell Lung Cancer 830Table 144: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 831Table 145: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Soft Tissue Sarcoma 833Table 146: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs 834Table 147: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Solid Tumor 835Table 148: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 837Table 149: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Squamous Cell Cancer 839Table 150: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Synovial Sarcoma 840Table 151: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of T-cell Lymphoma 841Table 152: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Testicular Cancer 842Table 153: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Thyroid Cancer 843Table 154: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Unspecified 845Table 155: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Vaccine adjunct 848Table 156: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Waldenstrom's hypergammaglobulinemia 848Table 157: Competitive Summary by Investigator of Angiogenesis Affecting Drug Development 849Table 158: Summary Table of Corporate Changes in the Competitive Landscape of Angiogenesis Affecting Drug Development in Oncology 853Table 159: Example of a Competitive Fall-Out Table (Targeting KDR/Modified) 861Table 160: Abbott's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 867Table 161: Acceleron Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 876Table 162: Access'Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 880Table 163: Active Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 884Table 164: Adherex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 889Table 165: Advantagene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 896Table 166: Advaxis'Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 902Table 167: Advenchen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 906Table 168: Aeterna Zentaris'Include

To order this report:Pathology Industry: Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

Mon, 06 Feb 2012 09:07:24 +0000

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

PR Newswire

NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

http://www.reportlinker.com/p0769020/World-Market-for-Anti-Infectives-Antifungals-Antibacterials-and-Antivirals- .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment:

Antifungals (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals)

The report covers both currently marketed and late stage development products. Revenues for each segment were generated using dollar and unit sales for each product.

A novel approach of this report is it provides revenue

by product type

but also the 'market' for treatments

by type of infection

, enabling the marketer to research the best markets where a variety of products may be implemented.

The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers.

The area of anti-infectives represents an exciting frontier for development of potential life-saving products. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer's ability to successfully operate in the market. The issues and trends affecting this market include:

Drug Resistance

HIV Trends, Cost, and Access to Drug Therapy

Other Immunocompromised Population Issues

Alliances and Partnerships

New Developments

Rx-to-OTC Switches

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction

Scope and Methodology

Total Size and Growth of the Market

Issues and Trends Affecting Market

Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

Overview

Introduction to Pathogens

Demographics of the World

Life Expectancy

Infections and Drug Resistance

Causes of Drug Resistance

Drug Resistance in Select Populations

Measures for Reducing Resistance

HIV Trends

Manufacturer and Marketer Trends

Trends in Partnerships and Alliances

Developers Trends

Aradigm

ARD-3100

Phase II

Cystic fibrosis

ARD-3150

Phase II

Bronchiectasis

ARD-1100

Preclinical

Inhalation anthrax

Trends in Rx-to-OTC Switches

CHAPTER THREE: ANTIFUNGAL DRUGS

Overview

Types of Fungal Infections

Superficial

Systemic

General Fungal Infection Statistics

Fungal Infection Risk

Description of Antifungal Products

Systemic Antifungals

Topical Antifungals

Market Overview

Total Market Size and Forecast

Antifungal Market by Product Type

Antifungal Market by Geographical Region

Market Analysis by Treated Condition

Competitive Analysis

Leading Products

CHAPTER FOUR: ANTIBACTERIAL DRUGS

Overview

Classification of Antibacterial Organisms

Antimicrobial Spectrum

Bacterial Resistance

Principles of Anti-bacterial Therapy

Combination Therapy and Prophylactic Use

Bacterial Infection Statistics

Bacterial Infection Risk

Classifications of Antibacterial Products

Aminoglycosides

Carbapenems

Cephalosporins

Macrolides

Penicillins

Quinolones

Sulfonamides

Tetracyclines

Market Overview

Total Market Size and Forecast

Antibacterial Market by Product Type

Antibacterial Market by Geographical Region

Market Analysis by Treated Condition

Competitive Analysis

Leading Products

CHAPTER FIVE: ANTIVIRAL DRUGS

Overview: Introduction to Viruses

Examples of Pathogenic Viruses

Virus Function and Life History

Replication in DNA Viruses

Replication of RNA Viruses

Replication in Retroviruses

Host Defenses Against Viruses 8

Viral Ploys to Invade Host Cells and Circumvent Host Responses

Invasion of Host Cells

Subversion of the Immune Response

Avoidance of Immune Detection and Attack by Killer Cells

HIV and AIDS

Viral Infection Statistics

Description of Antivirals Products

Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors

Protease Inhibitors

Other Antivirals

Market Overview

Total Market Size and Forecast

Antiviral Market by Product Type

Antiviral Market by Geographical Region

Market Analysis by Treated Condition

Competitive Analysis

Leading Products

CHAPTER SIX: MARKET SUMMARY

Market by Product Segment (Antifungals, Antibacterials, Antivirals)

CHAPTER SEVEN: CORPORATE PROFILES

Introduction

Abbott Laboratories

Astellas

AstraZeneca

Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)

Bristol-Myers Squibb

Cubist

Daiichi Sankyo

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Pfizer

Roche

APPENDIX: COMPANY DIRECTORY

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015

Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2011

Figure 1-2: World Market for Anti-Infectives Estimated Market Share of Leading Suppliers, 2011

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

Table 2-1: World Population by Selected Geographical Region, 2010 - 2050

Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2009

Figure 2-2: Average Life Expectancy in Years by Country 1980 and 2009

Table 2-3: Worldwide HIV/AIDS Infections

Table 2-4: Women Living with HIV/AIDS, by Region 2001 to 2009, Number

Table 2-5: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, 2009 based on 2010 WHO Guidelines

Table 2-6: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, by Selected Countries, 2009 based on 2010 WHO Guidelines

Table 2-7: Anti-Infective Drugs in Development by Developer

Table 2-8: Anti-infectives Ingredients Transferred from Rx-to-OTC Status

Figure 2-3: Anti-infectives Ingredients Transferred from Rx-to-OTC by Year

CHAPTER THREE: ANTIFUNGAL DRUGS

Table 3-1: Incidence of Infections by Type, 2010

Figure 3-1: Incidence of Infections by Type, 2010

Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Table 3-3: Treatment Options for Fungal Infections , (Type, Brand, and Manufacturer)

Table 3-4: The World Market for Antifungal Drugs 2007-2015

Figure 3-3: The World Market for Antifungal Drugs 2007-2015

Table 3-5: Antifungal Drug Market by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2011 and 2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Table 3-6: The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2007-2015

Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Geographic Region 2007-2015

Table 3-7: World Antifungal Market Estimated Products Sales by Infection Type , (Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)

Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2011 Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)

Table 3-8: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011

Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers, 5-year Comparison 2007-2011

Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Suppliers, 2011

Table 3-9: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011

Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011

CHAPTER FOUR: ANTIBACTERIAL DRUGS

Table 4-1: Antibiotics with Difficult Penetration

Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections, 2010

Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections

Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Figure 4-2: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Table 4-4: Treatment Options for Bacterial Infections , (Type, Brand, and Manufacturer)

Table 4-5: The World Market for Antibacterial Drugs 2007-2015

Figure 4-3: The World Market for Antibacterial Drugs 2007-2015

Table 4-6: Antibacterial Drug Market by Type 2007-2015

Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type, 2007-2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2011 and 2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

Table 4-7: The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2007-2015

Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Geographic Region 2007-2015

Table 4-8: World Antibacterial Market Estimated Products Sales by Infection Type , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)

Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2011 , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)

Table 4-9: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011

Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers 2007-2011

Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2011

Table 4-10: World Market for Antibacterial Drugs Estimated Sales of Select Products 2007-2011

CHAPTER FIVE: ANTIVIRAL DRUGS

Table 5-1: Host Cell Receptors

Table 5-2: Estimated World and U.S. Incidence of Viral Infections, 2010

Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections

Table 5-3: Treatment Options for Viral Infections , (Type, Brand, and Manufacturer)

Table 5-4: The World Market for Antiviral Drugs 2007-2015

Figure 5-2: The World Market for Antiviral Drugs 2007-2015

Table 5-5: Antiviral Drug Market by Type 2007-2015

Figure 5-3: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2007-2015

Figure 5-4: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2011 and 2015

Table 5-6: The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2007-2015

Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Geographic Region 2007-2015

Table 5-7: World Antiviral Market Estimated Products Sales by Infection Type (HIV, Hepatitis, Other Infections, Total)

Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2011 (HIV, Hepatitis, Other Infections, Total)

Table 5-8: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009

Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers 2007-2011

Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Suppliers, 2011

Table 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011

Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011

CHAPTER SIX: MARKET SUMMARY

Table 6-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015

Figure 6-1: The World Market for Anti-Infective Drugs 2007-2015

Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2011

Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2015

To order this report:Drug and Medication Industry: World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

Market Research Report

Check our

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference

Mon, 06 Feb 2012 09:00:00 +0000

Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference

PR Newswire

BLUE BELL, Pa., Feb. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the 14th Annual BIO CEO and Investor Conference.

BIO CEO & Investor Conference
February 13-14
New York City, NY
301 Park Avenue, Waldorf=Astoria

Inovio Presentation
February 13
11:00-11:30 a.m. EST

A live and archived webcast of the presentation will be accessible on Inovio's website at http://www.inovio.com/

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

* * *

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and synthetic vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable synthetic vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the quarter ended September 30, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com

SOURCE Inovio Pharmaceuticals, Inc.

Shanghai Pharmaceuticals Acquires 100% Stake in Kony Pharma to Optimize Industry Chain and Create Synergy

Mon, 06 Feb 2012 05:15:00 +0000

Shanghai Pharmaceuticals Acquires 100% Stake in Kony Pharma to Optimize Industry Chain and Create Synergy

PR Newswire

HONG KONG, Feb. 6, 2012 /PRNewswire-Asia/ -- Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group; stock code: 601607.SH; 02607.HK), is pleased to announce that 2012 marks a year that Shanghai Pharmaceuticals uses the proceeds from its H-share listing to step up M&A efforts. Subsequent to its purchase of a 51% equity stake in Jinhe Bio-Technology in January this year, Shanghai Pharmaceuticals has decided to acquire 70% stake in Changzhou Kony Pharm Co., Ltd. ("Kony Pharma") and the remaining 30% in the following two years in a bid to increase investment in special active pharmaceutical ingredients (APIs), optimize the pharmaceutical industry full value chain and achieve synergy.

The global generic drug market has seen a growth higher than the average of the pharmaceutical industry and doubles that of proprietary medicines in recent years. IMS Health gives an estimate of 9% to 12% growth in the global generic drug market over the next five years. Such growth in generic drugs is expected to rapidly boost the demand for special APIs from the pharmaceutical sector and presents a great opportunity for the development of the special API companies. Producing new generation, low-polluting special APIs with high gross margin and high added value relies on techniques, quality control, environment, health and safety (EHS) management system, and experience in international certification. Shanghai Pharmaceuticals was one of the first Chinese companies to export APIs to Europe and the U.S markets. Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals, passed the FDA certification in 1990 as well as the subsequent on-site checks.

Engaged in special APIs and intermediary businesses, Kony Pharma focuses on anti-virus and cardiovascular areas. Its major products, including valaciclovir and valsartan, are technologically advanced, cost effective with high gross margin and market share. They also meet international quality standards. 50% of Kony Pharma's products are exported and will see great potential in the global market once they pass CEP and FDA certifications. After the acquisition, Shanghai Pharmaceuticals can help Kony Pharma enhance its EHS management system and step up its efforts in international certification. Kony Pharma, on the other hand, can leverage on extensive relationships between Shanghai Pharmaceuticals and its multinational peers to open up sales channels for existing products. The deal will also enrich anti-virus and cardiovascular product offerings of Shanghai Pharmaceuticals, increasing its competitiveness in these areas.

As a vertically integrated pharmaceutical group, Shanghai Pharmaceuticals has an advantage in reducing the overall costs to raise competitiveness, with a focus on the development of APIs as well as preparations. APIs cannot be sold to the public without preparations, while preparations would have no source without APIs. Their relationship is like water without a source, a tree without roots. That is why both APIs and preparations are needed for the development of new products. In recent years, Shanghai Pharmaceuticals has made incremental investment in R&D. Some of the products under development are undergoing pilot trials and commercialization. Shanghai Pharmaceuticals will need a special API production base with advanced facilities, professional teams and stronger commercialization ability to accelerate the pace of new product launch. In addition to the Shanghai Xinghuo base and the Jiangsu Rudong base, Kony Pharma is expected to become one of the key API pilot trial and commercialization bases for Shanghai Pharmaceuticals.

Kony Pharma recorded revenue of RMB62.93 million for the sales of special APIs in the first half of 2011, with the net profit reached RMB17.25 million. The revenue for 2011 is expected to reach RMB115 million and Kony Pharma is expected to maintain a rapid growth in the future. Both parties agree that, subsequent to the first stage acquisition of 70% stake purchase, the remaining 30% will be acquired in the following two years at an agreed price subject to financial results and business growth.

Mr. Lu Mingfang, Executive Director and Chairman of Shanghai Pharmaceuticals, said, "We have strived to boost our overall competitiveness, enhance our position in the pharmaceutical industry and gradually increase our market share. We believe that after our acquisition of Jinhe Bio-Technology, the takeover of Kony Pharma will help us optimize the pharmaceutical industry chain and achieve synergy, which will in turn drive our business growth as well as profitability and create greater value for shareholders and investors. We will also continue to seek M&A deals which facilitate our development and accelerate our moves to develop nationwide presence."

About Shanghai Pharmaceticals Holding Co., Ltd.

Shanghai Pharmaceuticals is the only integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets. It was China's second-largest pharmaceutical distributor and third-largest pharmaceutical producer. The Group adopts an integrated vertical business model and provides solutions in pharmaceutical manufacturing, distribution, logistics storage and retail. The Group currently offers more than 400 pharmaceutical products as well as pharmaceutical distribution and supply chain solutions to more than 7,600 hospitals and medical institutions in China. The Group also operates approximately 1,700 self-operated and franchise stores nationwide.

Disclaimer:

This Press Release is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Shanghai Pharmaceuticals.

For further information, please contact:

Porda Havas International Finance Communications Group

Keely Chan +852-3150-6760 keely.chan@pordahavas.com

Kelly Fung +852-3150-6763 kelly.fung@pordahavas.com

Mokka Mok +852-3150-6737 mokka.mok@pordahavas.com

Peggy Cheung +852-3150-6753 peggy.cheung@pordahavas.com

Fax: +852-3150-6728

SOURCE　Shanghai Pharmaceticals Holding Co., Ltd.

Unity Management Group Announces Additions to Executive Management Team, Acquisition, and Additional Contracts

Fri, 03 Feb 2012 17:12:03 +0000

Unity Management Group Announces Additions to Executive Management Team, Acquisition, and Additional Contracts

PR Newswire

EAST HANOVER, N.J., Feb. 3, 2012 /PRNewswire/ -- Unity Management Group, Inc. (OTC: UYMG) (or "the Company") announced today Dr. Michael Levin has joined its wholly owned subsidiary Metropolitan Computing Corporation (or MCC) to manage product development, develop new business, and expand relationships with major pharmaceutical companies. Increased demand for products and services sold by Unity Management Group has resulted in management expecting to increase sales more than 300% for 2012.

Dr. Levin has more than 25 years of experience in the field of pharmaceutical technology and instrumentation as a consultant and a vendor of data acquisition and control systems for tablet presses, mixers, roller compactors and other equipment for Fortune 500 pharmaceutical companies. He has been a consultant to such pharmaceutical companies as Bristol-Myers Squibb, Merck, Sandoz/Novartis, and Warner-Lambert/Pfizer.

Born in Riga, Latvia, he received his M.Sc. at Hebrew University in Jerusalem and Ph.D. in Biomathematics (1980) from University of Washington in Seattle. Dr. Levin is a member of the American Association of Pharmaceutical Scientists (AAPS), International Society for Pharmaceutical Engineering (ISPE), and Biomedical Engineering Society (BMES).

Dr. Levin has published numerous scientific papers in various peer-reviewed journals on the topics ranging from coronary microcirculation to rheology of pharmaceutical blends. Dr. Levin has also taught various training courses and seminars on tableting and regulatory compliance, as well as wet granulation. These courses include workshops for the FDA and AAPS, as well as numerous presentations on the functionality and benefits of instrumented equipment, process monitoring, principles of Scale-Up and Post-Approval Changes (SUPAC) guidance and Process Analytical Technology (PAT).

Dr. Michael Levin is recognized worldwide as the editor of a well-known "Pharmaceutical Process Scale-Up" handbook, which is now in its 3rd edition. Dr. Levin has contributed chapters on "Tablet Press Instrumentation" and "Wet Granulation: End-Point Determination and Scale-Up" in the Encyclopedia of Pharmaceutical Technology.

"Dr. Levin is a great addition to our executive leadership team. He brings experience, leadership and a reputation as an industry expert that will take Unity Management Group to the next level," said Unity Management Group President, Michael Oliver.

MCC has also been awarded four contracts for February by major Pharmaceutical companies. The combined value of the contracts is valued at over $200,000.00 and includes the two contracts announced on January 26, 2012. The contracts are with Purdue, Forest Labs, Novartis, and Bristol Meyers Squib include upgrades on software systems and instrumentation on existing tablet presses, as well as calibration and upgrades on MCC's Patented Presster Tablet Press

MCC has agreed to acquire Donald A. Myers Machining and Manufacturing Service. MCC has outsourced machine work to Donald A. Myers Machining and Manufacturing Service in the past. Management believes this acquisition will pass major savings in production costs on to its clients. With new product development this will be a major breakthrough for MCC. Additional details on the acquisition are forthcoming.

Year End Financials are due out February 25, 2012. Negotiations on debt reduction are also expected to begin soon with Dutchess Capital.

UYMG will continue to grow, and bring value to its shareholders, diversifying and working on bringing more acquisitions to the company.

"We have worked very hard to lay the necessary ground work to expand UYMG and increase shareholder value to the next level. We will continue to work hard for our shareholders and are plan to develop positive momentum with the upcoming milestones we are focusing on in 2012. We will be announcing these as they are completed," said Michael Oliver Vice President of Unity Management group Inc. Mr. Oliver continued, "With Dr. Michael Levin on board, the new contracts, the increase in our sales, and the upcoming acquisition, we believe shareholders will be very pleased with our results."

About Unity Management Group, Inc.

Unity Management Group, a health resource company, will continue to provide innovative physician practice management services that offer high value and significant return on investment for physicians practices and hospitals through its three subsidiary companies: United Healthcare Solutions Inc., Unity Technologies Inc., and United Business Services Inc.

The first subsidiary, Unity Business Services, is a full service management company offering solutions in practice management, billing, staffing, contracting, licensing, credentialing, and accounting. Unity Business Services also offers assistance in HIPAA compliance, marketing, and unique solutions for practice start-ups and new practices.

Unity Technologies Inc. is a complete software solutions company offering billing, electronic medical records, and electronic health records for physicians' offices and hospitals.

United Healthcare Solutions, a national company based in Nevada, is a healthcare company will be providing medical, vision and dental plans, as well as PPO and HMO networks.

For more information please go to our website which can be found at

www.unitymanagementgroup.com www.mcc-online.com

Certain information discussed in this press release may constitute forward-looking statements within the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, it can give no assurance that its expectations will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to unpredictable and unanticipated risks, trends and uncertainties such as the Company's inability to accurately forecast its operating results; the Company's potential inability to achieve profitability or generate positive cash flow; the availability of financing; and other risks associated with the Company's business. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.

Unity Management Group, Inc.
Investor Relations
(855) 413-0755

SOURCE Unity Management Group, Inc.

Medicago Announces Investment in Quebec City Pilot Production Facility

Fri, 03 Feb 2012 12:00:00 +0000

Medicago Announces Investment in Quebec City Pilot Production Facility

PR Newswire

QUEBEC CITY, Feb. 3, 2012 /PRNewswire/ - Medicago Inc. (TSX : MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it plans to invest approximately $4 million to enhance the capacity of the pilot production facility located in Quebec City. The Company expects this investment to accelerate preclinical and clinical development timelines of future product candidates. This new investment includes capital expenditures and labour costs, as well as preclinical studies for a rabies vaccine and other products.

"Investing in our Quebec City facility is an important step for Medicago as we look towards expanding our product candidate pipeline," said Andrew Sheldon, President and CEO of Medicago. "We are happy to invest in our local community with the addition of approximately 20 new employees in 2012."

"We would like to thank CQDM for their past support of the VLPExpress™ platform, which has allowed us to accelerate our discovery and development of new vaccines," said Louis-Philippe Vezina, Chief Scientific Officer of Medicago. "The VLPExpress™ platform is now a key component in the development of our new products."

In 2009, Medicago was awarded $1.77 million in funding by the Quebec Consortium for Drug Discovery (CQDM) to support the development of VLPExpress™, an automated high-throughput platform enabling the rapid expression, purification and testing of VLPs to identify the best antigen presentations for a disease-causing agent within ten weeks.

"Medicago was one of the recipients of the first CQDM competition. Our financial support and unique collective approach allowed Medicago to strengthen its leadership position and increase its capacity to develop new products," said Max Fehlmann, President and CEO of CQDM. "We are very proud to be a part of Medicago's remarkable success. This reinforces the role of CQDM in promoting innovation and creating economic value for the research community in Quebec."

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The Company is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary VLP and manufacturing technologies. Medicago is a worldwide leader in the development of VLP vaccines using a transient expression system which produces recombinant vaccine antigens in plants. This technology has potential to offer more potent vaccines with speed and cost advantages over competitive technologies, enabling the development of a vaccine for testing in approximately one month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic, and supply large volumes of vaccine antigens to the world market. Medicago also intends to expand development into other areas such as biosimilars and biodefense products where the benefits of our technologies can make a significant difference. Additional information about Medicago is available at www.medicago.com.

About the CQDM
The Québec Consortium for Drug Discovery (CQDM) is a meeting ground for all stakeholders in biopharmaceutical research. Its principal mission is to fund research projects carried out in partnership between the academic and hospital milieus in the public sector and the pharmaceutical and biotechnology industries in the private sector. An innovative Canadian initiative, the CQDM has a twofold goal: to accelerate the drug discovery process and to develop safer and more effective drugs. Project funding is made possible through contributions from the Ministère du Développement Économique, de l'Innovation et de l'Exportation (MDEIE) du Québec, the Fonds de recherche Québec - Santé (FRQ-S), the Business-Led Networks of Centres of Excellence (BL-NCE), Pfizer Canada, AstraZeneca, Merck, Boehringer Ingelheim (Canada) Ltd., GlaxoSmithKline and Eli Lilly Canada Inc. For more information: www.cqdm.org.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Medicago's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Medicago or its management. The forward-looking statements are not historical facts, but reflect Medicago's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the matters discussed under "Risks Factors and Uncertainties" in Medicago's Annual Information Form filed on March 31, 2011 with the regulatory authorities. Medicago assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

SOURCE Medicago Inc.

New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients

Fri, 03 Feb 2012 07:00:00 +0000

New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients

PR Newswire

PARIS, Feb. 3, 2012 /PRNewswire-Asia/ --

-- "SARAH" - a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma is now open for recruitment

The start of SARAH, a new randomized controlled trial to directly compare the effectiveness of radioembolization with yttrium-90 resin microspheres (SIR-Spheres(R) microspheres; Sirtex Medical Limited, Australia) versus sorafenib (Nexavar(R), Bayer HealthCare Pharmaceuticals, Germany), a systemic therapy that is the current standard of care for patients with non-surgical advanced hepatocellular carcinoma (HCC), was announced today by the principal investigator, Professor Valerie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris, Clichy and Universite Paris Diderot, Sorbonne Paris Cite, France.

SARAH (SorAfenib versus Radioembolization in Advanced Hepatocellular carcinoma) is a Phase III multi-centre prospective randomized open-labelled trial, which aims to recruit 400 patients in France with advanced HCC (Barcelona Clinic Liver Cancer stage C) with or without portal vein thrombosis and no extrahepatic spread, who are ineligible for surgical resection, liver transplantation or radiofrequency ablation; or whose disease has progressed or recurred after previous therapies(1).

The primary goal of the study will be to assess if radioembolization with yttrium-90 resin microspheres provides an increased survival benefit compared to sorafenib in patients with advanced HCC.

Professor Vilgrain said: "Around 20 specialist cancer centres throughout France will be involved in this trial. SIR-Spheres microspheres were selected for the test arm of this collaborative trial, which is being promoted by the 'Assistance Publique - Hopitaux de Paris'".

In patients with advanced HCC, sorafenib is now the standard treatment. Its use is associated with an increased median overall survival (from 8 to 11 months in the SHARP trial) but 80% of patients also experience treatment-related adverse events.

Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumours. It is a minimally-invasive treatment, in which millions of radioactive SIR-Spheres microspheres (diameter between 20-60 microns) are infused via a catheter into the liver, where they selectively target liver tumours with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue. There is a growing interest in radioembolization using yttrium-90 resin microspheres in this patient population, based on a substantial number of open-label single-group studies as well as a large multi-centre European analysis(2) of the long-term outcomes related to survival and safety of radioembolization using SIR-Spheres microspheres in patients with inoperable HCC. In 13 open-label single-group studies totalizing 400 patients with advanced HCC, the combined estimation of the median overall survival after radioembolization with yttrium-90 microspheres was of 15 months (min-max: 7 to 27 months).

SIR-Spheres microspheres are approved for use in Australia, the European Union (CE Mark), New Zealand, Switzerland, Turkey and several other countries including in Asia (e.g. India, Korean, Singapore and Hong Kong) for the treatment of unresectable liver tumours. SIR-Spheres microspheres are also indicated in the U.S. for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine.

Professor Vilgrain said that: "The SARAH trial is testing the hypothesis that radioembolization using yttrium-90 resin microspheres can increase the median overall survival with fewer side effects and/or a better quality of life in comparison with sorafenib. We hope that the results of this study will help improve the prognosis for these difficult to treat patients."

About Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) occurs in people whose livers have become severely damaged or cirrhotic, due to conditions such as hepatitis and alcoholism. It is one of the ten most-common cancers in the world, with nearly 750,000 cases diagnosed annually, and the third-leading cause of cancer deaths(3). It occurs with greatest frequency in regions where viral hepatitis B or C aremost often diagnosed, such as in Asia Pacific and Southern Europe.

Hepatocellular cancer can be cured by surgery, either by resecting the diseased parts of the liver, or by transplantation with a liver from a healthy donor. These interventions, however, are inappropriate for the great majority of patients, whose survival may range from a few months to two or more years depending largely on the state of their liver at the time of their diagnosis and the extent of tumour invasion.

References:

-- SorAfenib versus Radioembolization in Advanced Hepatocellular carcinoma (SARAH): http://clinicaltrials.gov/ct2/show/NCT01482442.

-- Sangro B, Carpanese L, Cianni R et al on behalf of European Network on Radioembolization with yttrium-90 resin microspheres (ENRY). Survival after [90]Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation. Hepatology 2011; 54: 868-878.

-- GLOBOCAN. Liver Cancer Incidence and Mortality Worldwide in 2008. http://globocan.iarc.fr/factsheets/cancers/liver.asp accessed 28 June 2011.

SOURCE　Sirtex Medical Limited

Auxogyn Completes $20 Million In Series A Funding

Thu, 02 Feb 2012 14:00:00 +0000

Auxogyn Completes $20 Million In Series A Funding

-- Advances Early Embryo Viability Assessment (Eeva™) to Improve In Vitro Fertilization Outcomes --

PR Newswire

MENLO PARK, Calif., Feb. 2, 2012 /PRNewswire/ -- Auxogyn, Inc., a privately-held company focused on advancing women's reproductive health, today announced the close of the final tranche of its Series A financing, bringing the total funding to $20 million. The initial tranche was placed in May 2010, and investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures.

"Over the course of the last year, we have executed an aggressive operating plan in preparation for the commercialization of our first product, Eeva. Importantly, we expect to announce data from our five-site, 150-patient clinical study in the months ahead that will then be used as part of our regulatory filings in Europe and the United States," said Lissa Goldenstein, president and chief executive officer of Auxogyn.

"In evaluating investments throughout the medical technology field, we were impressed with Auxogyn's unique approach of bringing scientific rigor and data analytics backed by a robust intellectual property portfolio and top-tier clinical advisors to a market in desperate need of improved results," said Mark Gudiksen, Ph.D., principal of TPG Biotech and member of Auxogyn's board of directors.

"As the leader in fertility, Merck Serono is committed to investing in innovative technologies to improve the chance of a successful IVF pregnancy," said Nilesh Kumar Ph.D., director, Merck Serono Ventures. "This investment reflects our confidence in achieving this goal."

"Having developed its first product, initiated a substantive clinical study, and built a sound organizational infrastructure, Auxogyn has set the stage for an exciting 2012, springboarding toward commercialization in the latter half of the year," said Beth Seidenberg, M.D., partner at Kleiner Perkins Caulfield and Byers and a member of the Auxogyn board of directors.

About Eeva™
Auxogyn's non-invasive early embryo viability assessment (Eeva) system may improve IVF outcomes by providing IVF clinicians and patients with objective information on embryo viability. Eeva's proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters. With Eeva's quantitative data on each embryos' potential development, IVF clinicians can optimize the treatment path for their patients undergoing IVF procedures.

About Kleiner Perkins Caufield & Byers
Since its founding in 1972, Kleiner Perkins Caufield & Byers has backed entrepreneurs in more than 500 ventures including AOL, Amazon.com, Citrix, Compaq, Electronic Arts, Genentech, Genomic Health, Google, Intuit, Juniper Networks, Netscape, Sun, Symantec, Verisign, WebMD and Zynga. KPCB portfolio companies employ more than 350,000 people worldwide. More than 150 of the firm's portfolio companies have gone public, and many other KPCB ventures have achieved success through mergers and acquisitions. KPCB focuses its global investments in three practice areas - digital, greentech and life sciences - and provides entrepreneurs with company-building expertise out of its offices in Silicon Valley, Beijing and Shanghai.

About TPG Biotech
TPG Biotech is part of the growth equity and venture investment platform of TPG, the global private investment firm. With more than $1 billion under management, TPG Biotech targets investments in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, as well as industrial applications of biotechnology. TPG Biotech's investments in personalized medicine and genomics have included such companies as Genomic Health, XDx, CardioDx and Veracyte. Please visit www.tpgbiotech.com.

About Merck Serono Ventures
Merck Serono Ventures is the strategic, corporate venture capital fund of Merck Serono, the division for biopharmaceuticals of Merck KGaA. The fund invests in emerging biotechnology companies with the potential to provide breakthrough medical solutions in Merck Serono's focus therapeutic areas: Oncology, Neurodegenerative Diseases, Rheumatology, Fertility and Endocrinology. In addition, Merck Serono Ventures invests in companies developing innovative technologies that could enable the discovery and development of new products in its core therapeutic areas. For more information, visit www.merckserono.com

About Auxogyn
Auxogyn, Inc. is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The company's first product, Early Embryo Viability Assessment (Eeva), provides quantitative information regarding embryo development, to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, TPG Biotech and Merck Serono Ventures. For more information regarding Auxogyn please visit www.auxogyn.com.

SOURCE Auxogyn, Inc.

Mimi's Cafe® is the First Restaurant to Nationally Support the American Heart Association's Go Red For Women® Movement

Wed, 01 Feb 2012 18:28:04 +0000

Mimi's Cafe® is the First Restaurant to Nationally Support the American Heart Association's Go Red For Women® Movement

Monthlong fundraising effort kicks off on National Wear Red Day, Feb. 3; Guests rewarded for participating in the cause

PR Newswire

IRVINE, Calif., Feb. 1, 2012 /PRNewswire/ -- Mimi's Cafe Goes Red. Starting in February, American Heart Month, Mimi's Cafe is giving a piece of its heart to the American Heart Association's Go Red For Women movement. The neighborhood bistro inspired by France is the first-ever restaurant to nationally support the effort. Go Red For Women is dedicated to fighting heart disease, the number one killer of women, and harnessing the energy, passion and power women have to band together and collectively wipe out the disease.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/54331-mimi-s-cafe-american-heart-association-go-red-for-women-heart-month

(Photo: http://photos.prnewswire.com/prnh/20120201/MM44799 )

"We are honored to be the first restaurant to nationally support the American Heart Association's Go Red For Women movement," said Mark Mears, Mimi's President and Chief Concept Officer. "It is not only a cause that perfectly aligns with the values of our company, it is an issue that our guests care deeply about. We are dedicated to providing awareness and education, along with more healthy dining choices and helpful tips, so our guests have the tools they need to make heart healthy choices while dining out."

Mimi's is activating its heartfelt campaign on National Wear Red Day, Friday, Feb. 3. Guests who show their support by wearing red will receive a FREE cup of soup with any purchase to warm their heart. And throughout the month, guests will be invited to join in the fight against heart disease in women. For every $1 donation, guests can post a red heart-shaped tribute card on the giant in-restaurant red dress display. With a $5 donation, guests will also receive a commemorative red dress lapel pin. As a thank you for these donations, Mimi's will provide each guest with up to $35 in savings.

Heart disease is often silent, hidden and misunderstood. That is why in addition to fundraising, Mimi's is taking the lead to empower guests to make healthy decisions while dining out and share a lifesaving message about a disease that can be preventable.

"As the first restaurant to nationally support American Heart Association's Go Red For Women movement, Mimi's Cafe is playing an important role in the fight against heart disease, women's No. 1 killer," said William H. Roach Jr., Chairman of the Board of the American Heart Association. "We're thankful to Mimi's Cafe for helping Go Red For Women make ending heart disease a reality."

In addition, Mimi's will be going red on Facebook. Mimi's "Reasons to Go Red" app allows fans to share an inspirational message, alongside the fashionable Red Dress icon, to let their friends know why they are going red and encourage others to join the cause. Guests can also come into Mimi's to take a photo with a giant red dress display and upload it to a special "Mimi's Goes Red" Facebook gallery via QR Code. Which fan wears it best? Visit Mimi's Facebook page, facebook.com\mimiscafe, in February and show support of the Go Red For Women movement.

About Mimi's Cafe
Mimi's Cafe, a French-inspired casual dining restaurant, has 145 locations in 24 states as of the end of the second fiscal quarter (Oct. 28, 2011). Mimi's Cafe is a unit wholly owned by Bob Evans Farms, Inc., a publicly traded company (NASDAQ: BOBE), known and loved for its delicious breakfast, lunch and dinner menus, friendly service and charming, stylish decor.

About Go Red For Women
Go Red For Women is the American Heart Association's national movement, created by women, for women, dedicated to uncovering the truth about women and heart disease: heart disease can kill you or a woman you love. With more women dying of cardiovascular disease than all forms of cancer combined, we are committed to fighting this No. 1 killer that is preventable. For more information please visit GoRedForWomen.org or call 1-888-MY-HEART (1-888-694-3278). The American Heart Association's Go Red For Women movement is nationally sponsored by Macy's and Merck & Co., Inc, with additional support from our cause sponsors.

SOURCE Mimi's Cafe

World's Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event

Wed, 01 Feb 2012 14:00:00 +0000

World's Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event

PR Newswire

ZURICH, Feb. 1, 2012 /PRNewswire/ -- The buzz is growing stronger and stronger for one of the most talked-about events in 2012- the Pharma CI Europe Conference on February 21-22, 2012 at the Renaissance Zurich Hotel in Switzerland (http://pharmaciconference.com/ ). "With more than 150 top pharmaceutical executives already attending, people are already saying that this event is sure to make waves among the industry's influential decision makers," says conference organizer Amy Yueh. "After all, this event is the counterpart to our annual Pharma CI USA Conference, scheduled for September 11-12 in Parsippany, New Jersey, which is the largest gathering of biopharma competitive intelligence execs in the world with over 300 CI professionals attending annually."

Conference participants will benefit from the impressive speaking faculty of more than 40 expert speakers from prestigious companies like Actelion, Amgen, Bausch + Lomb, Chiesi Farmaceutici, DSM, F. Hoffmann-La Roche, GlaxoSmithKline, Helsinn Healthcare, Johnson & Johnson, MedImmune, Merck, Norbrook, Novartis, Nycomed, Onyx, Pfizer, Sanofi-Aventis, Shire, Takeda, Virbac, and many more!

These senior level speakers are prepared to delve deep into meaningful discussions about the latest and most pressing issues. To see the detailed program agenda, go to: http://www.pharmaciconference.com/EUR_program.html

The Pharmaceutical Competitive Intelligence Europe Conference provides the ideal atmosphere for learning and debating the industry's most pressing topics. This is the only event that brings together all the industry's decision makers and experts in an atmosphere that promotes gaining insight, developing and solidifying meaningful working relationships, and providing clear directives about the future of this important industry.

The 2012 Pharma CI Europe Conference sponsors/exhibitors include the following: Deallus Group; Lifescience Dynamics; Citeline; Pennside; Adis; BioMedTracker; Digimind; Evaluate Pharma; Evalueservce; Financial Times; Fletcher/CSI; Fuld & Company; ISIS; Larvol; PharmaVoxx; Prescient; SAI MedPartners; Sedulo Group; Value Edge.

The Pharma CI Conference is THE INDUSTRY'S GOLD STANDARD for senior level pharmaceutical, biotechnology, medical device, and diagnostics professionals seeking the latest news and the industry's best networking opportunities. More than 300 people attended the 2011 event in the U.S., and now it's Europe's turn!

For more information, go to http://pharmaciconference.com/ , call +1-212-228.7974, or email info@pharmaciconference.com

Contact:
Amy Yueh
Pharma CI Conference
+ 1 212 228 7974
www.pharmaciconference.com

SOURCE Pharma CI Conference

Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology

Wed, 01 Feb 2012 13:00:00 +0000

Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology

PR Newswire

The 'Prix Galien' Award – Biomedical industry's highest accolade for innovative research & development

NEW YORK, Feb. 1, 2012 /PRNewswire-USNewswire/ -- The Galien Foundation announced today open enrollment for the annual Prix Galien USA Awards to recognize outstanding achievement in improving the human condition through the development of innovative medical treatments and drug therapies. The 2012 awards ceremony will be held on October 16th in New York City. Awards will be bestowed for products in the following categories; Best Pharmaceutical Agent, Best Biotechnology Product, and Best Medical Technology. Companies seeking to enter the awards program must submit an entry by May 30th, 2012 to be eligible for consideration. Entry applications can be submitted online at www.prix-galien-usa.com.

(Photo: http://photos.prnewswire.com/prnh/20120201/DC44432-a )

(Logo: http://photos.prnewswire.com/prnh/20120201/DC44432LOGO-b )

The ceremony will also include special honors to select individuals who have served to better humanity -- entitled the ProBono Humanum Award.

About the Awards
The Prix Galien Award was created to honor medical research and pharmacology. Considered the biomedical industry's equivalent of the Nobel Prize, the Prix Galien is the highest industry honor for outstanding efforts to improve the human condition though approval of innovative treatments and medicines. Past product award recipients include; Prevnar 13® (Pfizer 2011), Stelara® (Janssen 2011), Prolia®/XGEVA® (Amgen 2011), Coartem® (Novartis 2010), RotaTeq® (Merck 2010), xTAG® (Luminex 2010), Gleevec® (Novartis 2009), Nplate® (Amgen 2009), Promacta® (GSK 2009), Cellsearch® (Veridex 2009), Isentress® (Merck 2009), Selzentry® (Pfizer 2008), Solis® (Alexion 2008), Infuse® (Wyeth 2008), Revlimid® (Celgene 2008), Januvia® (Merck 2007), Chantix® (Pfizer 2007), Humira® (Abbott 2007) and Gardisil® (Merck 2007).

The ProBono Humanum Award recognizes exemplary efforts by individuals and organizations in helping mankind. The award will be presented by Professor Elie Wiesel, a Nobel Prize Laureate. Previous winners of the award include: Professor Paul Farmer (2011), President Bill Clinton and Philippe Douste-Blazy (2010); Professors Barry Bloom and Jeffrey Sachs (2009), Sheldon Segal and the Population Council (2008); and Dr. Roy Vagelos (2007). For more information visit www.galienfoundation.org.

CONTACT:
John Mohr
The Galien Foundation
+1-973-809-5582
jgmohr@galienfoundation.org

SOURCE Galien Foundation